Zimmer Biomet Holdings Inc (NYSE: ZBH) reported Q1 FY23 adjusted EPS of $1.89 Tuesday, compared to $1.61 a year ago and the consensus estimate of $1.64.
It posted Q1 sales of $1.831 billion, up 10.1% on a reported basis and 13.2% on a constant currency basis. Revenues came in above the consensus of $1.7 billion.
"Our strong performance in Q1 outpaced our internal growth expectations, driven by continued procedure recovery, solid execution, and increasing traction around ZB innovation," said Bryan Hanson, Chairman, President & CEO of Zimmer Biomet.
Revenue from knee products increased 15% Y/Y to $762.5 million (+18.2% constant currency).
Monday, Zimmer Biomet agreed to acquire Ossis, a maker of personalized 3D-printed implants.
Ossis also offers complex hip replacements, including second-time replacements and ones involving bone tumors and trauma.
Hip products increased 9.3% to $492.8 million (+12.9%).
Guidance: Zimmer Biomet expects an adjusted EPS of $7.40-$7.50 for 2023, up from the prior forecast of $6.95-$7.15 per share previously forecast. Analysts, on average, were expecting a profit of $7.06 per share.
The company expects revenue to grow 5%-6% this year, compared with its previous forecast of 1.5%-3.5%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.